389 results about "Oxygenase" patented technology

The invention provides a modified variant of dicamba monooxygenase (DMO). The invention relates to the unexpected finding that cells expressing this DMO exhibit high levels of tolerance to the herbicide dicamba. Compositions comprising DMO-encoding nucleic acids and methods of use are provided.

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested/shown that C_20:5n-3 (and C_{22:6 n-3}) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.

Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

The present invention relates to novel monooxygenase nucleic acids and polypeptides created using mutagenesis, DNA shuffling, or both, in a single iteration or multiple iterations, and methods for their creation and use. The monooxygenase enzymes of the present disclosure have particular utility as biocatalysts in industrial chemical redox reactions, such as the oxidation of aromatic hydrocarbons, for example, toluene, benzene, or nitrobenzene, into industrially desirable products. The systems and processes of the present invention are especially useful for the coupled synthesis and recovery of catechols, methylcatechols, resorcinols, methylresorcinols, hydroquinones, methylhydroquinones, hydroxybenzenes, cresols, nitrobenzenes, and nitrohydroxyquinones.

The invention discloses a method for producing glucaric acid by constructing recombinant saccharomyces cerevisiae and fermenting and belongs to the technical field of bioengineering. The method comprises the following steps: knocking out an OPI gene of saccharomyces cerevisiae BY4741; introducing myo inositol-1-phosphate synthase and inositol monophosphatase from the saccharomyces cerevisiae, inositol from arabidopsis thaliana and uronic acid dehydrogenase from pseudomonas syringae into the saccharomyces cerevisiae through constitutive plasmid pY26-GPD-TEF, and realizing approach construction of the saccharomyces cerevisiae from glucose to the glucaric acid. According to the method disclosed by the invention, by use of a constructed metabolic pathway, non-selectivity, high energy consumption property and high cost performance of a chemical oxidation method are avoided; the low-priced glucose is directly transformed into D-glucaric acid with high added value by fermentation culture of engineering bacteria; the method has the advantages of mild reaction conditions, high transformation rate and fewer byproducts; production cost can be greatly reduced.

The invention relates to an oxygenase-bath alkali-free desizing process for a polyester/cotton high-count and high-density fabric. The process sequentially comprises the following steps of: sewing and singeing the fabric; washing the fabric with three-grid hot water; washing the fabric with two-grid coldwater; padding oxidation bleaching working solution; steaming at the temperature of 102 DEG C for 50 minutes; washing the fabric with four-grid hot water; drying; and shaping, wherein in the step of padding oxidation bleaching working solution, the formula of the oxidation bleaching working solution comprises 10g/L of high-efficient scouring agent HS-120B, 65g/L of 288 dispersing agent, 5g/L of scouring enzyme 188, 5g/L of wax regent WR, 10g/L of hydrogen peroxide stabilizing agent P and 14.0 to 15.0g/L of hydrogen peroxide (wherein the concentration is 33 percent). Compared with the prior art, the desized fabric has greatly improved quality, namely the handfeel is plump; the fabric surface loss ratio is low; the fabric surface whiteness is good; and the fabric has no cotton, multiple nodes and no alkaline spots.

The present invention provides a method for preparing a hybrid gene. The method includes a step of amplifying a P450 gene fragment contained in a sample using primers designed on the basis of regions of a plurality of P450 in which amino acid sequences are highly conserved and a step of preparing the hybrid gene using the amplified fragments and a known P450 gene. The method includes no culturing step or a step of normalizing extracted DNAs and is useful in isolating a P450 gene from various microbial resources.

The present invention further provides a fused cytochrome P450 monooxygenase containing a peptide which is linked to the C-terminus of a P450 protein with a linker portion disposed therebetween and which has the same function as that of a reductase domain contained in a cytochrome P450 monooxygenase originating from Rhodococcus sp. strain NCIMB 9784. This enables the construction of a high-efficiency electron transfer system useful for various P450 proteins and also enables the production of an active P450 monooxygenase.

Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.

Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1.

Algae and cyanobacteria are genetically engineered to have lower RUBISCO (ribulose-1,5-bisphosphate carboxylase/oxygenase) content in order to grow more efficiently at elevated carbon dioxide levels while recycling industrial CO₂ emissions back to products, and so as not to be able to grow outside of cultivation.

The invention belongs to the field of bioengineering and particularly relates to a flavin monooxygenase mutant and a preparation method thereof. The error-prone PCR technology is used to conduct random mutation on wild type flavin monooxygenase to obtain the flavin monooxygenase mutant. The specific enzyme activity of the flavin monooxygenase mutant is improved by 35% compared with that of the wild type flavin monooxygenase. Meanwhile, a yeast expression system is adopted, when the flavin monooxygenase is displayed on the surface of yeasts, yeast cells can serve as enzyme producers and can also serve as carriers in immobilized enzymes, operation of purification, fixation and the like of the enzymes are omitted, the production link is simplified, and the production cost is reduced.

The invention discloses cyclohexanone monooxygenase and an application thereof, in particular cyclohexanone monooxygenase obtained by site-specific mutagenesis and an application thereof. Compared with a SEQ ID NO: 1, the amino acid sequence of the cyclohexanone monooxygenase has gene mutation in at least one site as follows: serine Ser at the 386th site is mutated to asparagines Asn, and serine Ser at the 435th is mutated to threonine Thr. Experiments show that the cyclohexanone monooxygenase disclosed by the invention can catalytically convert a high concentration omeprazole thioether primerinto esomeprazole.

The use of fatty acid oxidizing enzymes in the manufacture of paper materials, such as paper, linerboard, corrugated paperboard, tissue, towels, corrugated containers and boxes. Examples of fatty acid oxidizing enzymes are oxygenases classified as EC 1.13.11. including any of the sub-classes thereof, such as lipoxygenase, EC 1.13.11.12. The effect of these enzymes is that the deposition of pitch is reduced, and bleaching and de-inking effects are also observed on the paper pulp and the resulting paper material. The fatty acid oxidizing enzyme can be used in combination with a substrate, with proteases, lipases, xylanases, cutinases, oxidoreductases, cellulases, endoglucanases amylases, mannanases, steryl esterases, and/or cholesterol esterases; or with surfactants and other adjuvants.

This invention pertains to development of a new animal model for Parkinson's Disease (PD) and to the discovery that elevated monoamine oxygenase B (MOA-B) expression and/or activity is a strong prognostic indicator for the disease. Accordingly, in certain embodiments, methods are provided for identifying a mammal at risk for Parkinson's disease. The methods typically involve determining level of expression or activity of monoamine oxidase B (MAO-B) in a sample from the mammal wherein an elevated level of MAO-B expression and/or activity as compared to a control (reference) is an indicator that the mammal has an increased likelihood of developing Parkinson's disease.

The present invention relates to a carotenoid cleavage dioxygenase CCD4a involved in the synthesis of gardenia jasminoides ellis crocin, an encoding gene and functions thereof, belongs to the technical field of gene engineering, and discloses the open reading frame sequence of a carotenoid cleavage dioxygenase CCD4a gene and the amino acid sequence encoded by the carotenoid cleavage dioxygenase CCD4a gene. According to the present invention, the CCD4a gene is screened based on transcriptomics, the functions of CCD4a are verified in vitro by using zeaxanthin as the substrate and constructing the pET28a-CCD4a prokaryotic expression vector, and the results prove that CCD4a has the functions of carotenoid cleavage dioxygenase so as to establish the foundation for the analysis and biosynthetic research of the crocin source pathway.

Treating or preventing inflammatory processes and diseases in dogs associated with the activity of inducible cyclo-oxygenase-2 (COX-2), while at the same time reducing or eliminating undesirable side effects associated with simultaneous inhibition of the activity of constitutive cyclo-oxygenase-1 (COX-1) by selectively inhibiting COX-2 activity with reference to COX-1 activity, wherein the selectivity ratio or COX-2:COX-1 activity inhibition is at least 3:1 based on ex vivo inhibition levels measured in whole blood; the inhibitor is a member selected from the group of anti-inflammatory compounds consisting essentially of salicylic acid derivatives, p-aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids, enolic acids, and alkanones; the inhibitor in particular is comprised of (+)(S)-enantiomer of 6-chloro-alpha-methyl-9H-carbazole-2-acetic acid.

Methods and systems for evaluating and predicting the reactivity of natural and engineered monooxygenase enzymes are provided. Methods are provided for acquiring a functional profile (fingerprint) of monooxygenases that encode information regarding the active site configuration of such monooxygenases. Methods are also provided for carrying out analysis of a monooxygenase fingerprint, to formulate predictions regarding the reactivity properties (e.g., substrate reactivity, chemo-, regio, and stereoselectivity properties) of the fingerprinted monooxygenases.

The invention discloses a method for producing glucaric acid by improving yeast fermentation by use of fusion expression and belongs to the field of metabolic engineering. According to the method, a myoinositol oxygenase (MIOX) and aldehyde acid dehydrogenase (Udh) are fused and then cloned and expressed in a yeast strain by virtue of direct fusion and addition of different connecting peptides, and therefore, the synthesis way of the glucaric acid is strengthened. By comparison, the yield of the Pichia pastoris GS115-Udh-(GS)1-MIOX is the highest; during shake-flask fermentation culture, 944.67mg/L of glucaric acid is generated in a YPD-MI (adding 10g/L myoinositol to a YPD culture medium) culture medium. During 3L fermentation tank culture, the yield of the glucaric acid can be 6.02g/L. According to the method, the policy of the metabolic engineering is adopted and a microbiological strain is modified to synthesize the target product glucaric acid; and as a result, a firm foundation is laid for efficient production of the glucaric acid by use of the biological method.

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.